On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
HOME > BUSINESS
BUSINESS
- Boehringer Japan’s Ethical Drug Sales Tick Up 2% in 2015
April 26, 2016
- Novartis Seeks Add’l Indications for Ilaris in Japan
April 26, 2016
- Novartis Looks to Harness Big Data for Indication Expansions: Global Medical Chief
April 26, 2016
- MSD, Sanofi to End RotaTeq, Heptavax Copromotion in Japan
April 25, 2016
- Janssen Files Simponi for Ulcerative Colitis in Japan
April 25, 2016
- Kaketsuken Continues to Suspend Production as Huge Damages Found
April 22, 2016
- Novo Nordisk’s Japan Sales Log Record 89 Billion Yen on Tresiba, Victoza
April 22, 2016
- Around 140 Clinical Trials of Nucleic Acid Drugs Underway Worldwide, with Cancer, Neuropathy, and Myopathy as Main Targets
April 22, 2016
- Mylan Japan Management, Labor Union Remain at Odds over Sales Rep Layoff
April 21, 2016
- Japan’s 1st PCSK9 Inhibitor Hits Market; MHLW Issues Notification to Prevent Hasty Use
April 21, 2016
- Ajinomoto Pulls Out from JV with Yoshindo as EA Pharma Launched
April 21, 2016
- MSD’s Hep C Drugs Get Priority Review Status in Japan
April 20, 2016
- Biogen Files MS Treatment Dimethyl Fumarate in Japan
April 20, 2016
- FunPep, Morishita Jintan Sign MOU to Commercialize Products Containing Antibacterial Peptide
April 19, 2016
- AbbVie Starts Japan PIIb/III Study of Selective JAK1 Inhibitor in RA Patients
April 19, 2016
- Heptares, Kymab Tie Up for Joint Research on Cancer Immunotherapy
April 19, 2016
- Wholesalers Say Drug Distributions in Quake-Hit Kumamoto More or Less Stable
April 19, 2016
- Sanwa Kagaku’s Kumamoto Factory Shuts Down after Quake
April 18, 2016
- Kaketsuken Halts Operations on April 18-20 after Quake
April 18, 2016
- Announcement: 9th Annual eyeforpharma Japan 2016 - Westin Tokyo, July 13-14
April 15, 2016
ページ
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…